Last updated: February 13, 2026
Overview of the Drug
NDC 00093-8118 refers to Xyrem (sodium oxybate), a central nervous system depressant indicated for the treatment of narcolepsy with cataplexy and excessive daytime sleepiness. Xyrem is marketed by Jazz Pharmaceuticals. Its high potency and Schedule III status influence its market dynamics.
Market Size and Demand Drivers
- Prevalence: Narcolepsy affects approximately 1 in 2,000 people in the U.S., translating to an estimated 150,000 to 200,000 patients. However, only about 25-30% are diagnosed and adequately treated.
- Competitive landscape: Currently, Xyrem faces limited competition, with newer therapies like Sunosi (solriamfetol) and Wakix (pitolisant) capturing some market share.
- Market penetration: Xyrem's usage depends heavily on specialist physicians, primarily sleep disorder clinics. Its administration complexity and side effect profile limit broader adoption.
- Reimbursement: Insurance coverage is generally favorable due to FDA approval, but high costs influence patient access and prescribing patterns.
Historical Sales Data and Market Trends
- Sales volume: In 2021, Xyrem's U.S. sales exceeded $600 million annually.
- Growth rate: Between 2018 and 2022, sales grew at an average annual rate of 3-5%, slowed by COVID-19 disruptions and emerging competitors.
- Pricing: The average wholesale price (AWP) per bottle ranges from $50,000 to $60,000, depending on dosage and quantity.
Pricing Analysis and Projections
| Year |
Estimated Average Price per Bottle |
Factors Influencing Future Prices |
| 2023 |
$55,000 |
Stable due to existing patents and market control |
| 2024 |
$55,500 |
Potential generic entry delayed; price stability remains |
| 2025 |
$56,000 |
patent exclusivity ending may introduce generics |
| 2026 |
$45,000–$50,000 (post-generic) |
Entry of generics expected to reduce prices by 10-20% |
Patent and Regulatory Landscape
- Patent protection: Originally held until 2023; patent cliff anticipated in 2024. Patent challenges and generic approvals likely to influence price and availability.
- Regulatory factors: Fast-track designations, FDA approvals for formulations, and potential new indications could impact market size.
Competitive Outlook
- New entrants: Multiple generics approved post-2023; their market entry will introduce price competition.
- Off-label use: Limited but growing use for other conditions may sustain revenues temporarily.
- Pricing strategies: Jazz Pharmaceuticals is expected to maintain high prices through patient assistance programs and formulary negotiations until patent expiry.
Future Market and Price Dynamics
- Pre-2024: Prices stay stable, driven by patent protection.
- Post-2024: Prices may decline 10-20% expectantly due to generic competition; total market may contract or stabilize dependent on new indications or formulations.
- Long-term: Market could stabilize around $300–400 million annual sales worldwide, assuming continued demand and limited competition outside generics.
Key Factors Influencing Price and Market
- Patent expiration: Accelerates generic entry, reducing prices.
- Regulatory approvals: New indications or formulations could renew growth.
- Market access and reimbursement policies: Influence patient affordability and prescribing behavior.
- Patient adherence: Complex administration may limit market expansion, keeping demand steady rather than explosive.
Summary
Xyrem (NDC 00093-8118) commands high prices due to patent protection, limited competition, and patient demand, with prices averaging approximately $55,000 per bottle. The expiration of patent exclusivity in 2024 will likely trigger significant price declines due to generics entering the market, potentially reducing average prices by 10-20%. Annual sales are projected to decline from current levels of roughly $600 million in the U.S. to around $300–400 million in the coming years, contingent upon regulatory developments and market acceptance of competitors.
Key Takeaways
- NDC 00093-8118 (Xyrem) is a dominant narcolepsy treatment with high current prices.
- Patent expiry in 2024 will trigger generic competition, rapidly impacting pricing.
- Market size depends on diagnosed but untreated patient populations and reimbursement dynamics.
- Price projections reflect a decline post-2024 due to generics, with downward pressure expected.
- Long-term revenue depends on regulatory developments, competitive entries, and formulary negotiations.
FAQs
-
When will generics enter the market for Xyrem?
Expected in late 2023 or early 2024, following patent cliff and FDA approvals.
-
How will generic entry affect market share?
Generics are likely to capture a significant portion, reducing Xyrem's market share and revenue.
-
Are there alternative therapies for narcolepsy?
Yes. Sunosi (solriamfetol) and Wakix (pitolisant) are newer options, but Xyrem remains the most prescribed for severe cases.
-
What factors could prolong Xyrem’s high prices beyond patent expiration?
Regulatory barriers, limited manufacturing capacity, or formulations with extended patent protection could sustain higher prices.
-
How does reimbursement influence Xyrem’s market?
Favorable reimbursement supports continued usage; however, high out-of-pocket costs may limit access for some patients.
Sources:
[1] IQVIA. 2022 U.S. Prescription Drug Market Data.
[2] Jazz Pharmaceuticals financial reports, 2021-2022.
[3] FDA Approvals and Patent Data Files.
